The CPDMU is a Shared Resource used by all AECC clinical cancer researchers that provides centralized management, communication, and oversight of all cancer clinical trials at the AECC. The CPDMU provides a central location for processing of all cancer related protocols, interaction with internal (e.g., IRB) and external (e.g., NCI, industry) agencies, and communication. The scope of work performed by the CPDMU includes processing of initial protocol submissions, amendments, internal and external safety and/or adverse event reports, and annual IRB progress reports, as well as patient registration, radiology review/tumor measurement, Data and Safety Monitoring Committee (DSMC reports, data management, and quality assurance). The CPDMU also supports other components of the clinical trials infrastructure, including the Protocol Review and Monitoring System (PRMS) and Protocol Specific Research Support (PSRS). Upon protocol activation, an announcement is distributed to all AECC investigators, and an updated list of currently active protocols is distributed on a monthly basis. The protocol status (open, suspended, closed to accrual) and most recently approved version of the protocol and IRB-approved consent is also posted on the CPDMU website so that it is accessible to all health care providers and research associates. Quality control functions include centralized education and training services for physicians, research nurses, physician assistants, and study coordinators. During the July 1, 2011 to June 30, 201212 grant year, the CPDMU processed 124 new protocols and 525 protocol amendments for review by the Protocol Review and Monitoring Committee (PRMC) and IRB, 5136 adverse events and 26 protocol monitoring reports for the DSMC, and 670 patient registrations requiring data management and processing.
The Central Protocol and Data Management Unit (CPDMU) provides centralized management communication, and oversight for all cancer related clinical trials at the Albert Einstein Cancer Center (AECC). As an NCI-designated Cancer Center, AECC contributes to the national effort to reduce morbidity and mortality from cancer.
|Tiwari, Sangeeta; van Tonder, Andries J; Vilchèze, Catherine et al. (2018) Arginine-deprivation-induced oxidative damage sterilizes Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 115:9779-9784|
|Celestrin, Kevin; Díaz-Balzac, Carlos A; Tang, Leo T H et al. (2018) Four specific immunoglobulin domains in UNC-52/Perlecan function with NID-1/Nidogen during dendrite morphogenesis in Caenorhabditis elegans. Development 145:|
|Haider, Afreen; Wei, Yu-Chen; Lim, Koini et al. (2018) PCYT1A Regulates Phosphatidylcholine Homeostasis from the Inner Nuclear Membrane in Response to Membrane Stored Curvature Elastic Stress. Dev Cell 45:481-495.e8|
|Cai, Ying; Lin, Jhih-Rong; Zhang, Quanwei et al. (2018) Epigenetic alterations to Polycomb targets precede malignant transition in a mouse model of breast cancer. Sci Rep 8:5535|
|Li, Ke; Baker, Nicholas E (2018) Regulation of the Drosophila ID protein Extra macrochaetae by proneural dimerization partners. Elife 7:|
|Xie, Xianhong; Xue, Xiaonan; Strickler, Howard D (2018) Generalized linear mixed model for binary outcomes when covariates are subject to measurement errors and detection limits. Stat Med 37:119-136|
|Carvajal, Luis A; Neriah, Daniela Ben; Senecal, Adrien et al. (2018) Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Sci Transl Med 10:|
|Boku, S; Izumi, T; Abe, S et al. (2018) Copy number elevation of 22q11.2 genes arrests the developmental maturation of working memory capacity and adult hippocampal neurogenesis. Mol Psychiatry 23:985-992|
|Mendez-Dorantes, Carlos; Bhargava, Ragini; Stark, Jeremy M (2018) Repeat-mediated deletions can be induced by a chromosomal break far from a repeat, but multiple pathways suppress such rearrangements. Genes Dev 32:524-536|
|Schloss, Jennifer; Ali, Riyasat; Racine, Jeremy J et al. (2018) HLA-B*39:06 Efficiently Mediates Type 1 Diabetes in a Mouse Model Incorporating Reduced Thymic Insulin Expression. J Immunol 200:3353-3363|
Showing the most recent 10 out of 1508 publications